Factors considered in selecting patients for adjuvant therapy include tumor-specific factors, such as tumor size, axillary node metastasis, and tumor biology (i.e. ER/PR and HER2 expression, multiparameter gene expression assays), and patient specific factors such as age, comorbidities, and patient preference. This evidence concerns the gene ERBB2 and neoplasm.